Zytiga Clinical Trials

Browse 63 Zytiga Medical Studies Across 387 Cities

14 Phase 3 Trial · 994 Zytiga Clinics

Reviewed by Michael Gill, B. Sc.
10 Zytiga Clinical Trials Near Me
Top Cities for Zytiga Clinical Trials
Image of New York in New York.
New York
25Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site
Image of Houston in Texas.
22Active Trials
M D Anderson Cancer CenterTop Active Site
Zytiga Clinical Trials by Phase of Trial
N/A Zytiga Clinical Trials
1Active Zytiga Clinical Trials
1Number of Unique Treatments
0Number of Active Locations
Most Recent Zytiga Clinical Trials

What Are Zytiga Clinical Trials?

Zytiga is the brand name for the drug called abiraterone acetate, a drug that is used in the treatment of prostate cancer. The drug is developed by Janssen-Cilag, after being introduced by the Institute of Cancer Research. Zytiga is typically used in conjunction with other treatments in the treatment of prostate cancer, and is often used after surgical treatment where the testicles are removed to remove all cancerous tissue. Zytiga clinical trials are specialized research studies that serve the purpose of testing the different ways that Zytiga can be used, and the different populations it is most successful with.

Why Is Zytiga Being Studied In Clinical Trials?

Zytiga is being studied in clinical trials because it is a cancer treatment that can be successful in a wide range of treatment options. The medication was first developed in 1995 and was approved by the Federal Drug Administration (FDA) in 2011. It is the FDA that determines the safety and potential efficacy or effectiveness of a medication. When the FDA wants more information to approve a drug, it will often ask for continued clinical trials upon approval. Even with full FDA approval, continued Zytiga clinical trials are beneficial to many different populations in different phases of treatment for prostate cancer.

How Does Zytiga Treatment Work?

The disease of prostate cancer is a disease that is connected to the male hormones, and those hormones can contribute to the progression of prostate cancer. Zytiga works to suppress the production of male hormones, specifically testosterone, to slow down or stop prostate tumors from starting or growing.

What Are Some of the Breakthrough Clinical Trials Involving Zytiga?

There are always Zytiga clinical trials in progress to determine the best ways to treat with Zytiga, and the best populations to use it on. As Zytiga is often used in conjunction with other medications for prostate cancer, researchers are always looking for the most valuable and efficient ways to prescribe the medication. Here are some of the most comprehensive breakthrough Zytiga clinical trials.

2011: In this Zytiga clinical trial for the _English Journal of Medicine _Zytiga is used with over 1195 males to determine if it works on patients whose cancer is resistant to surgery and who have already received chemotherapy. Results indicated a longer survival time by four months with patients in the Zytiga group over patients in the placebo group.

2013: This Zytiga clinical trial with 1088 participants was run by researchers for the English Journal of Medicine, where researchers looked at how Zytiga would work for patients that had not received chemotherapy for prostate cancer. The Zytiga treatment group showed a 57 percent reduction in death as a result of the disease as well as a 25 percent decrease in the risk of death from the disease.

Who Are The Key Opinion Leaders On Zytiga Clinical Trial Research?

Professor Michael Zarman

Professor Michael Zarman was the lead researcher for the Institute of Cancer Research and one of the world’s discoverers of Zytiga. His team ran Zytiga clinical trials to formulate the medication and in turn won a Royal Society of Chemistry award. He has published more than 120 articles on cancer research in his career.

Bagi R.P. Jana, M.D.

Bagi R.P. Jana is a professor in the department of general oncology in the Division of Cancer Medicine at the University of Texas and has been instrumental in the publication of many leading Zytiga clinical trials and their publication.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: August 11th, 2023

References1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5. https://pubmed.ncbi.nlm.nih.gov/255594152 Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020 May;17(5):271-291. doi: 10.1038/s41585-020-0297-9. Epub 2020 Mar 17. Review. https://pubmed.ncbi.nlm.nih.gov/322033063 Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020 May;17(5):271-291. doi: 10.1038/s41585-020-0297-9. Epub 2020 Mar 17. https://pubmed.ncbi.nlm.nih.gov/322033064 Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, O'Neill LA, Xavier RJ. Trained immunity: A program of innate immune memory in health and disease. Science. 2016 Apr 22;352(6284):aaf1098. doi: 10.1126/science.aaf1098. Epub 2016 Apr 21. Review. https://pubmed.ncbi.nlm.nih.gov/271024895 Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17. https://pubmed.ncbi.nlm.nih.gov/332173626 Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020 Jun;20(6):375-388. doi: 10.1038/s41577-020-0285-6. Epub 2020 Mar 4. Review. https://pubmed.ncbi.nlm.nih.gov/321326817 Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106-119. doi: 10.1016/j.eururo.2016.02.028. Epub 2016 Mar 17. Review. https://pubmed.ncbi.nlm.nih.gov/269966598 Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2. https://pubmed.ncbi.nlm.nih.gov/328775769 Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. Front Immunol. 2018 Dec 17;9:2936. doi: 10.3389/fimmu.2018.02936. eCollection 2018. Review. https://pubmed.ncbi.nlm.nih.gov/3061929610 Gershon RC, Rothrock N, Hanrahan R, Bass M, Cella D. The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas. 2010;11(3):304-14. https://pubmed.ncbi.nlm.nih.gov/20847477